- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Intraocular Melanoma - April 2002
National Cancer Institute®
Last Modified: April 1, 2002
Table of Contents
1
UI - 11884898
AU - Shields JA; Shields CL; Naseripor M; Eagle RC; Miller J
TI -
Choroidal melanoma in a black patient with oculodermal melanocytosis.
SO - Retina 2002 Feb;22(1):126-8
AD - Oncology Service and Department of Pathology, Wills Eye Hospital, Thomas
Jefferson University, Philadelphia, Pennsylvania 19107, USA.
2
UI - 11879148
AU - Wilson DJ; Klein ML
TI -
Choroidal melanoma treated with cryotherapy.
SO - Arch Ophthalmol 2002 Mar;120(3):393-5
AD - Casey Eye Institute, Oregon Health & Science University, 3375 SW
Terwilliger Blvd, Portland, OR 97201-4197, USA. wilsonda@ohsu.edu
3
UI - 11879152
AU - Wilson DJ; Klein ML
TI -
Cryotherapy as a primary treatment for choroidal melanoma.
SO - Arch Ophthalmol 2002 Mar;120(3):400-3
AD - Casey Eye Institute, Oregon Health Sciences University, 3375 SW
Terwilliger Blvd, Portland, OR 97201, USA. wilsonda@ohsu.edu
4
UI - 11905603
AU - Ruiter D; Bogenrieder T; Elder D; Herlyn M
TI -
Melanoma-stroma interactions: structural and functional aspects.
SO - Lancet Oncol 2002 Jan;3(1):35-43
AD - The Wistar Institute, Philadelphia, PA, USA. d.ruiter@pathol.azn.nl
Cutaneous melanomas are notorious for their tendency to metastasise.
Because the tumour microenvironment plays an important part in tumour
development and progression, we review the structural and functional
aspects of interactions between melanoma and the stroma. We emphasise
fibrovascular patterns (both in uveal and cutaneous melanoma), cellular
and extracellular composition of the stroma, and the molecules involved.
Also, we discuss functional interactions, focusing on
melanoma-fibroblast cross-talk by soluble factors and by direct
cell-cell contact. On the basis of recent findings we propose that
involvement of fibroblasts in melanoma-stromagenesis occurs through
different stages: recruitment, activation, and conversion to
myofibroblasts, or differentiation to fibrocytes. We reason that this
involvement is topographically linked to different areas in and around
the tumour, and hypothesise that stromal activation, as seen in tumor
ulceration or immunological regression in melanoma, stimulates tumour
progression.
5
UI - 11853726
AU - Romaniuk W; Koziol H; Muskalski K; Dorecka M; Tarnawska D; Sabat D
TI -
A unique case of primary corneal melanoma.
SO - Jpn J Ophthalmol 2002 Jan-Feb;46(1):114-6
AD - Department of Ophthalmology, Silesian School of Medicine, St. Barbara
Specialist Hospital, Sosnowiec, Poland.
PURPOSE: To report a unique case of primary corneal melanoma. METHODS: A
59-year-old white woman underwent keratectomy to remove a pigmented
rapidly enlarging growth on the corner of her left eye. The specimen was
submitted for histopathologic examination. RESULTS: Ophthalmic
examination disclosed no association with limbal or conjunctival
melanocytic abnormalities. Histopathologic studies demonstrated nodular
malignant melanoma. CONCLUSION: Possible development of primary corneal
melanoma should be considered in diagnosing all cases with a past
history of corneal melanin pigmentation.
6
UI - 11934320
AU - Iwamoto S; Burrows RC; Kalina RE; George D; Boehm M; Bothwell MA;
TI -
Schmidt R
Immunophenotypic differences between uveal and cutaneous melanomas.
SO - Arch Ophthalmol 2002 Apr;120(4):466-70
AD - Department of Medicine, Division of Dermatology, University of
Washington Medical Center, Box 356524, Seattle, WA 98195-6524, USA.
siwamoto@u.washington.edu
OBJECTIVE: To determine the immunophenotypic differences between uveal
and cutaneous melanomas, employing standard melanoma markers as well as
p75 neurotrophin receptor (p75NTR) and microphthalmia transcription
factor (MITF). DESIGN: Fifteen uveal melanomas (5 spindle, 5
epithelioid, and 5 mixed uveal subtypes) were immunolabeled with a panel
of antibodies that included S100, tyrosinase, melan-A, HMB-45 and HMB-50
combination, MITF, and p75NTR. The results were tabulated on the basis
of intensity and pervasiveness of the labeling and compared with a prior
study on cutaneous spindle and epithelioid melanomas. RESULTS: In
contrast to its strong labeling of cutaneous melanomas, S100
immunolabeling of uveal melanomas was weak and variable. p75NTR, known
to differentiate spindle from epithelioid melanomas of the skin, did not
immunolabel uveal melanomas. HMB-45, HMB-50, tyrosinase, melan-A, and
MITF immunolabeled all uveal melanomas strongly, irrespective of the
histologic subtype, but not cutaneous melanomas. Microphthalmia
transcription factor was especially clear in its labeling of uveal
melanomas. CONCLUSIONS: Although cutaneous and uveal melanomas share
many molecular markers in common, there are differences between the 2
types of melanoma. First, the level of expression of S100 differs
between cutaneous and uveal melanomas. Second, while cutaneous melanomas
can be further subdivided into spindle and epithelioid types based on
their immunophenotype, the uveal melanomas cannot.
7
UI - 11934337
AU - Biswas J; Krishnakumar S; Shanmugam MP
TI -
Uveal melanoma in Asian Indians: a clinicopathological study.
SO - Arch Ophthalmol 2002 Apr;120(4):522-3
8
UI - 11309305
AU - Tschentscher F; Prescher G; Horsman DE; White VA; Rieder H; Anastassiou
TI -
G; Schilling H; Bornfeld N; Bartz-Schmidt KU; Horsthemke B; Lohmann DR;
Zeschnigk M
Partial deletions of the long and short arm of chromosome 3 point to two
tumor suppressor genes in uveal melanoma.
SO - Cancer Res 2001 Apr 15;61(8):3439-42
AD - Institut fur Humangenetik, Universitatsklinikum Essen, Hufelandstrasse
55, D-45122 Essen, Germany.
Uveal melanoma is the most common form of primary eye cancer. Monosomy
3, which is an unusual finding in tumors but is present in approximately
50% of uveal melanomas, is significantly correlated with metastatic
disease. To obtain positional information on putative tumor suppressor
genes on this chromosome, we have investigated tumors from 333 patients
by comparative genomic hybridization, microsatellite analysis, or
conventional karyotype analysis. A partial deletion of the long arm was
found in eight tumors, and the smallest region of deletion overlap (SRO)
spans 3q24-q26. We found six tumors with a partial deletion of the short
arm and were able to define a second SRO of about 2.5 Mb in 3p25. This
SRO does not overlap with the VHL gene. Our finding suggests a role for
two tumor suppressor genes in metastasizing uveal melanoma and may
explain the loss of an entire chromosome 3 in these tumors.
9
UI - 11931804
AU - Laquis SJ; Freeman JM; Fleming JC; Wilson MW; Haik BG
TI -
A rapidly growing choroidal melanoma.
SO - Am J Ophthalmol 2002 Apr;133(4):580-1
AD - Department of Ophthalmology, University of Tennessee Health Science
Center, Memphis, Tennessee 38163, USA.
PURPOSE: We describe a rapidly growing choroidal melanoma that failed to
respond to consecutive globe-sparing treatments in an individual with
ocular melanocytosis. DESIGN: Interventional case report. METHODS: A
53-year-old man with right ocular melanocytosis, decreased vision in the
right eye, and right eye pain was referred for suspected choroidal
melanoma. The lesion, which measured 2.4 mm x 6.6 mm x 6.0 mm, was
treated with transpupillary thermotherapy on two occasions and with
iodine-125 (I-125) plaque brachytherapy, both of which failed.
Enucleation allowed histologic analysis. RESULTS: At enucleation, the
choroidal melanoma in the right eye measured 13.6 mm x 16.5 mm x 16.9
mm, which demonstrated the most rapid growth and doubling time reported
in a tumor of this type thus far. Pathologic analysis classified the
tumor as a mixed-cell type. CONCLUSION: This case reiterates the
association between ocular melanocytosis and choroidal melanoma,
provides additional evidence that rapid growth and doubling time may be
associated with transpupillary thermotherapy and I-125 plaque failure,
and highlights the need to follow those tumors closely.
10
UI - 11913882
AU - Lee V; Sandy C; Rose GE; Moseley IM; Cree I; Hungerford JL
TI -
Primary orbital melanoma masquerading as vascular anomalies.
SO - Eye 2002 Jan;16(1):16-20
AD - Moorfields Eye Hospital, London, UK.
PURPOSE: To review two cases of primary orbital melanoma presenting like
orbital vascular anomalies. METHODS: Retrospective review of clinical
presentation, treatment, radiology and pathology for two patients under
the care of the Orbital Clinic at Moorfields Eye Hospital. RESULTS: Both
lesions presented with the appearance and behaviour of vascular
anomalies. In one case, a spindle cell melanoma appeared to be a low
flow vascular anomaly with a loculated secondary haemorrhage and, in the
other case, a melanoma of soft parts was considered to be an
arteriovenous malformation and responded partially to embolisation.
CONCLUSION: Primary malignant melanoma may present as a secondary
vascular lesion of the orbit and this very rare tumour should be
considered in the differential diagnosis of any vascular anomaly.
11
UI - 11864894
AU - Eskelin S; Kivela T
TI -
Mode of presentation and time to treatment of uveal melanoma in Finland.
SO - Br J Ophthalmol 2002 Mar;86(3):333-8
AD - Department of Ophthalmology, Helsinki University Central Hospital,
Helsinki, Finland. sebastian.eskelin@hus.fi
AIMS: To investigate the current referral pattern and delays in
treatment of patients with primary uveal melanoma. METHODS: 184
consecutive Finnish patients with uveal melanoma diagnosed between July
86%). Their mean age was 60 years (range 14-87). The dates of visits to
dispensing optician, physician, ophthalmologist and ocular oncologist,
the presence of symptoms, and reason for consultation were determined by
structured telephone interview. Time intervals to treatment planning and
treatment were calculated. RESULTS: 139 patients (87%) had symptoms at
presentation and 44 patients (28%) had been seen by an ophthalmologist
less than 2 years previously. The median height of the tumour was 6 mm
(range, 1.0-17.0) and its largest basal diameter 11 mm (range 2.5-22.0)
at diagnosis. Melanoma developed from a previously detected presumed
naevus in 13 patients (8%). When the first contact was a dispensing
optician (15%) the median time to treatment planning was 22 days (range
1-1156). When a physician other than an ophthalmologist (19%) was
contacted the delay was 68 days (range 0-1283) and when an
ophthalmologist (65%) was seen it was 34 days (range 1-1426). These
differences were not significant (p=0.32). The chance of being referred
at first visit was 89%. Median time to treatment was not associated with
symptoms (p=0.16) and tumour volume (p=0.29), but it was significantly
different between patients who were and were not referred at first visit
(140 days v 34 days; p<0.001) and between those treated by ruthenium and
iodine brachytherapy (59 days v 33 days; p=0.009). CONCLUSIONS: Analysis
of delays in management indicates that earlier treatment could be
achieved if dilated fundus examinations were performed without
exceptions, all suspicious naevi were referred for a second opinion, and
if the patients with melanoma were referred to the ocular oncology
service concurrently with staging examinations done at the regional
hospital.
12
UI - 11864904
AU - Tsai T; O'Brien JM; Engstrom R; Straatsma BR
TI -
Extrascleral extension of a choroidal melanoma after argon
photocoagulation and transpupillary thermotherapy.
SO - Br J Ophthalmol 2002 Mar;86(3):358-9
13
UI - 11944865
AU - Mueller A J; Bartsch D U; Schaller U; Freeman W R; Kampik A
TI -
Imaging the microcirculation of untreated and treated human choroidal
melanomas.
SO - Int Ophthalmol 2001;23(4-6):385-93
AD - Augenklinik der Universitat, Munchen, Germany.
INTRODUCTION: Histologically demonstrable microcirculation patterns
(microcirculation pattern) of human choroidal melanomas have prognostic
significance for the patient. We report on our experience in imaging
these microcirculation pattern in vivo using simultaneous confocal
Fluorescein (FA)- and Indocyaninegreen (ICG) angiography before and
after brachytherapy. PATIENTS AND METHODS: The simultaneously procured
confocal FA- and ICG angiograms of 50 patients with untreated choroidal
melanomas were studied for the visibility of microcirculation pattern.
Patients were also followed with simultaneous FA/ICG after
brachytherapy. RESULTS: Confocal FA disclosed signs of tumor
vascularization in 12 (24%) of the 50 examined patients but
microcirculation pattern only in 3 patients (6%). In contrast,
simultaneously obtained confocal ICG disclosed microcirculation pattern
in 47 patients (94%). In 10 (77%) of the 13 patients the tumor
microcirculation changed considerably after brachytherapy: Distortion,
thickening, thinning, as well as complete obliteration of vessels could
be observed. CONCLUSION: Histologically demonstrated microcirculation
pattern can be imaged in vivo. This offers the possibility to assess the
likely biologic behavior of the individual tumor without the need for
obtaining a cytologic or histologic specimen via enucleation or
fine-needle biopsy. Confocal ICG angiogiography images microcirculation
pattern better than FA which can be explained by the different
absorption-, fluorescence- and exudation-characteristics ICG. Follow-up
with confocal ICG of choroidal melanomas after brachytherapy shows
different features and allows for visualization of the microcirculation
reaction to the treatment which might be a useful tool for studying the
effects of future anti-angiogenesis based tumor therapies.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
